Abstract
Perimenopause marks a time of change in a woman’s hormonal environment, which is apparent from the resultant irregular periods and vasomotor symptoms. These symptoms can start in the early 40s and continue through to the early 50s. Migraine is also affected by hormonal fluctuations, particularly the natural decline in estrogen in the late luteal phase of the menstrual cycle. This effect of estrogen “withdrawal” on migraine appears to become more predominant during perimenopause. Despite the increased prevalence of headache and migraine in women in their 40s, migraine is underdiagnosed in this population. In women attending with symptoms suggestive of perimenopause, it is important to ask about headache symptoms. Once diagnosed, a number of strategies can be used to manage both perimenopausal migraine and menopausal symptoms effectively, with the potential to reduce the associated morbidity.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Santoro N, Brown J, Adel T, Skurnick J: Characterization of reproductive hormonal dynamics in the perimenopause. J Clin Endocrinol Metab 1996, 81:1495–1501.
Stewart WF, Wood C, Reed ML, et al.: Cumulative lifetime migraine incidence in women and men. Cephalalgia 2008, 28:1170–1178.
Wober C, Brannath W, Schmidt K, et al.: Prospective analysis of factors related to migraine attacks: the PAMINA study. Cephalalgia 2007, 27:304–314.
MacGregor EA, Barnes D: Migraine in a specialist menopause clinic. Climacteric 1999, 2:218–223.
Hodson J, Thompson J, al-Azzawi F: Headache at menopause and in hormone replacement therapy users. Climacteric 2000, 3:119–124.
Mattsson P: Hormonal factors in migraine: a population-based study of women aged 40 to 74 years. Headache 2003, 43:27–35.
Sabia S, Fournier A, Mesrine S, et al.: Risk factors for onset of menopausal symptoms. Results from a large cohort study. Maturitas 2008, 60:108–121.
Wang SJ, Fuh JL, Lu SR, et al.: Migraine prevalence during menopausal transition. Headache 2003, 43:470–478.
Neri I, Granella F, Nappi R, et al.: Characteristics of headache at menopause: a clinico-epidemiologic study. Maturitas 1993, 17:31–37.
Granella F, Sances G, Zanferrari C, et al.: Migraine without aura and reproductive life events: a clinical epidemiological study in 1300 women. Headache 1993, 33:385–389.
Oldenhave A, Jaszmann LJ, Everaerd WT, Haspels AA: Hysterectomized women with ovarian conservation report more severe climacteric complaints than do normal climacteric women of similar age. Am J Obstet Gynecol 1993, 168:765–771.
Freeman EW, Sammel MD, Lin H, et al.: Symptoms in the menopausal transition: hormone and behavioral correlates. Obstet Gynecol 2008, 111:127–136.
MacGregor EA, Igarashi H, Wilkinson M: Headaches and hormones: subjective versus objective assessment. Headache Q 1997, 8:126–136.
Couturier EG, Bomhof MA, Neven AK, van Duijn NP: Menstrual migraine in a representative Dutch population sample: prevalence, disability and treatment. Cephalalgia 2003, 23:302–308.
Somerville BW: Estrogen-withdrawal migraine. I. Duration of exposure required and attempted prophylaxis by premenstrual estrogen administration. Neurology 1975, 25:239–244.
Somerville BW: Estrogen-withdrawal migraine II. Attempted prophylaxis by continuous estradiol administration. Neurology 1975, 25:245–250.
Epstein MT, Hockaday JM, Hockaday TD: Migraine and reproductive hormones throughout the menstrual cycle. Lancet 1975, 1:543–548.
Lichten EM, Lichten JB, Whitty A, Pieper D: The confirmation of a biochemical marker for women’s hormonal migraine: the depo-estradiol challenge test. Headache 1996, 36:367–371.
MacGregor EA, Frith A, Ellis J, et al.: Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen. Neurology 2006, 67:2154–2158.
Martin VT, Wernke S, Mandell K, et al.: Defining the relationship between ovarian hormones and migraine headache. Headache 2005, 45:1190–1201.
Miro F, Parker SW, Aspinall LJ, et al.: Sequential classification of endocrine stages during reproductive aging in women: the FREEDOM study. Menopause 2005, 12:281–290.
Miro F, Parker SW, Aspinall LJ, et al.: Relationship between follicle-stimulating hormone levels at the beginning of the human menstrual cycle, length of the follicular phase and excreted estrogens: the FREEDOM study. J Clin Endocrinol Metab 2004, 89:3270–3275.
Martin VT, Behbehani M: Ovarian hormones and migraine headache: understanding mechanisms and pathogenesis-part I. Headache 2006, 46:3–23.
Berman NE, Puri V, Chandrala S, et al.: Serotonin in trigeminal ganglia of female rodents: relevance to menstrual migraine. Headache 2006, 46:1230–1245.
Andrikoula M, Prelevic G: Menopausal hot flushes revisited. Climacteric 2009, 12:3–15.
MacGregor EA: Migraine, the menopause and hormone replacement therapy: a clinical review. J Fam Plann Reprod Health Care 2007, 33:245–249.
MacGregor EA: Perimenstrual headaches: unmet needs. Curr Pain Headache Rep 2008, 12:468–474.
Pringsheim T, Davenport WJ, Dodick D: Acute treatment and prevention of menstrually related migraine headache: evidence-based review. Neurology 2008, 70:1555–1563.
Warren MP, Kulak J Jr: Is estrogen replacement indicated in perimenopausal women? Clin Obstet Gynecol 1998, 41:976–987.
MacGregor EA: Headache and hormone replacement therapy in the postmenopausal woman. Curr Treat Options Neurol 2009, 11:10–17.
Mueller L: Predictability of exogenous hormone effect on subgroups of migraineurs. Headache 2000, 40:189–193.
Aegidius KL, Zwart JA, Hagen K, et al.: Hormone replacement therapy and headache prevalence in postmenopausal women. The Head-HUNT study. Eur J Neurol 2007, 14:73–78.
Misakian AL, Langer RD, Bensenor IM, et al.: Postmenopausal hormone therapy and migraine headache. J Womens Health (Larchmt) 2003, 12:1027–1036.
MacGregor EA, Frith A, Ellis J, et al.: Prevention of menstrual attacks of migraine: a double-blind placebo-controlled crossover study. Neurology 2006, 67:2159–2163.
Scarabin PY, Oger E, Plu-Bureau G: Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003, 362:428–432.
Nappi RE, Cagnacci A, Granella F, et al.: Course of primary headaches during hormone replacement therapy. Maturitas 2001, 38:157–163.
Nappi RE, Sances G, Sommacal A, et al.: Different effects of tibolone and low-dose EPT in the management of postmenopausal women with primary headaches. Menopause 2006, 13:818–825.
Lippert TH, Filshie M, Muck AO, et al.: Serotonin metabolite excretion after postmenopausal estradiol therapy. Maturitas 1996, 24:37–41.
Facchinetti F, Nappi RE, Tirelli A, et al.: Hormone supplementation differently affects migraine in postmenopausal women. Headache 2002, 42:924–929.
Rossouw JE, Anderson GL, Prentice RL, et al.: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002, 288:321–333.
Salpeter SR, Walsh JM, Greyber E, Salpeter EE: Brief report: coronary heart disease events associated with hormone therapy in younger and older women. A metaanalysis. J Gen Intern Med 2006, 21:363–366.
Pines A, Sturdee DW, Birkhauser MH, et al.: IMS updated recommendations on postmenopausal hormone therapy. Climacteric 2007, 10:181–194.
Kaiser HJ, Meienberg O: Deterioration of onset of migraine under oestrogen replacement therapy in the menopause. J Neurol Neurosurg Psychiat 1993, 240:195–197.
MacGregor A: Estrogen replacement and migraine aura. Headache 1999, 39:674–678.
Steiner TJ, Ahmed F, Findley LJ, et al.: S-fluoxetine in the prophylaxis of migraine: a phase II double-blind randomized placebo-controlled study. Cephalalgia 1998, 18:283–286.
d’Amato CC, Pizza V, Marmolo T, et al.: Fluoxetine for migraine prophylaxis: a double-blind trial. Headache 1999, 39:716–719.
Ozyalcin SN, Talu GK, Kiziltan E, et al.: The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache 2005, 45:144–152.
Bulut S, Berilgen MS, Baran A, et al.: Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. Clin Neurol Neurosurg 2004, 107:44–48.
Mathew NT, Rapoport A, Saper J, et al.: Efficacy of gabapentin in migraine prophylaxis. Headache 2001, 41:119–128.
Di Trapani G, Mei D, Marra C, et al.: Gabapentin in the prophylaxis of migraine: a double-blind randomized placebo-controlled study. Clin Ter 2000, 151:145–148.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
MacGregor, E.A. Migraine headache in perimenopausal and menopausal women. Current Science Inc 13, 399–403 (2009). https://doi.org/10.1007/s11916-009-0065-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11916-009-0065-2